BACKGROUND: The pancreas is a rare site of metastases, although metastatic renal cell carcinoma (mRCC) is the most commonly reported secondary tumor. Pancreatectomy has been described in selected patients with localized metastases, but long-term benefit remains poorly defined. METHODS: A retrospective review of a prospectively maintained database was performed to evaluate the outcomes of patients undergoing pancreatectomy for mRCC at a tertiary care center from 1995-2017. Postoperative complications were evaluated using the Modified Accordion Grading System (MAGS) and Kaplan-Meier curves and log-rank tests were utilized for survival analysis. RESULTS: 29 patients underwent pancreatectomy for mRCC including 15 distal pancreatectomies (DP), 10 pancreaticoduodenectomies (PD) and 4 total-pancreatectomies (TP). The mean age was 67 ± 8 years, and 15 were male. The median time from index nephrectomy to pancreatectomy was 8 (IQR: 3.72-12.2) years. There was no 90 Day post-pancreatectomy mortalities and the morbidity incidence included 13 Minor MAGS and 8 Severe MAGS complications respectively. Post-pancreatectomy disease specific survival at 2- and 4-years were 89% and 80% with 12 patients being alive at last follow up. CONCLUSIONS: Pancreatic resection can be safely performed in select patients with localized mRCC with favorable long-term outcomes.
BACKGROUND: The pancreas is a rare site of metastases, although metastatic renal cell carcinoma (mRCC) is the most commonly reported secondary tumor. Pancreatectomy has been described in selected patients with localized metastases, but long-term benefit remains poorly defined. METHODS: A retrospective review of a prospectively maintained database was performed to evaluate the outcomes of patients undergoing pancreatectomy for mRCC at a tertiary care center from 1995-2017. Postoperative complications were evaluated using the Modified Accordion Grading System (MAGS) and Kaplan-Meier curves and log-rank tests were utilized for survival analysis. RESULTS: 29 patients underwent pancreatectomy for mRCC including 15 distal pancreatectomies (DP), 10 pancreaticoduodenectomies (PD) and 4 total-pancreatectomies (TP). The mean age was 67 ± 8 years, and 15 were male. The median time from index nephrectomy to pancreatectomy was 8 (IQR: 3.72-12.2) years. There was no 90 Day post-pancreatectomy mortalities and the morbidity incidence included 13 Minor MAGS and 8 Severe MAGS complications respectively. Post-pancreatectomy disease specific survival at 2- and 4-years were 89% and 80% with 12 patients being alive at last follow up. CONCLUSIONS:Pancreatic resection can be safely performed in select patients with localized mRCC with favorable long-term outcomes.
Authors: Maxine Sun; Rodolphe Thuret; Firas Abdollah; Giovanni Lughezzani; Jan Schmitges; Zhe Tian; Shahrokh F Shariat; Francesco Montorsi; Jean-Jacques Patard; Paul Perrotte; Pierre I Karakiewicz Journal: Eur Urol Date: 2010-10-28 Impact factor: 20.096
Authors: Neel P Chudgar; Murray F Brennan; Rodrigo R Munhoz; Peter R Bucciarelli; Kay See Tan; Sandra P D'Angelo; Manjit S Bains; Matthew Bott; James Huang; Bernard J Park; Valerie W Rusch; Prasad S Adusumilli; William D Tap; Samuel Singer; David R Jones Journal: J Thorac Cardiovasc Surg Date: 2017-03-21 Impact factor: 5.209
Authors: Sushanth Reddy; Barish H Edil; John L Cameron; Timothy M Pawlik; Joseph M Herman; Marta M Gilson; Kurtis A Campbell; Richard D Schulick; Nita Ahuja; Christopher L Wolfgang Journal: Ann Surg Oncol Date: 2008-09-11 Impact factor: 5.344